BPC-157 Side Effects and Safety: What the Research Shows

Reviewed by Thomas Okafor, Peptide Chemist · Last reviewed October 12, 2026

Ask whether BPC-157 has side effects and you’ll get two confident answers online. One camp says it has none. The other lists nausea, dizziness and headaches with suspiciously precise percentages. Both claim more than the research can support. The answer that fits the data is shorter: almost nobody has studied it in people.

That gap is the subject of this page. It lays out what each kind of study has actually found, from animal toxicology to the one small human safety pilot, which risks researchers and regulators have raised in theory, and which questions nobody has tested yet. It doesn’t rate BPC-157 as safe or unsafe for humans. The evidence to do that doesn’t exist.

BPC-157 Safety at a Glance

BPC-157 has a reassuring animal toxicology record and almost no human safety data. A four-species toxicology program reported nothing toxic at the levels it used. Across three tiny human studies, 30 people in all, investigators logged zero adverse events. No controlled human trial or long-term study has been published.

Side Effects Reported So Far, by Source

Side-effect information on BPC-157 comes from three very different sources: animal toxicology studies, which found no toxicity; a handful of small human pilots, which recorded no adverse events; and anecdotal reports online, which describe symptoms but can’t show cause. Only the first two count as research evidence.

Findings from animal toxicology studies

🐭 Most of the animal safety evidence comes from one paper: Xu’s team published a preclinical safety package for BPC-157 in Regulatory Toxicology and Pharmacology in 2020. Across mice, rats, rabbits and dogs, the authors saw no meaningful toxicity, no damage to genetic material and no effects on developing offspring.

Findings from the small human pilot

👤 The study designed to look at safety is Lee and Burgess, 2025, an intravenous pilot in 2 healthy adults. Blood tests for heart, liver, kidney, thyroid and glucose markers didn’t change, and neither participant reported side effects. Two earlier studies from the same clinical group, a 16-person knee case series and a 12-person bladder pilot, also recorded no adverse events, though neither was set up to measure safety systematically.

Anecdotal and clinic reports

Online reports and some clinic blogs describe nausea, headache, dizziness, fatigue and injection-site redness. These are anecdotes. They come with no control group, no verified product and no way to tell coincidence from cause. Some websites attach exact percentages to these symptoms without naming a study, and we couldn’t trace those figures to any published source, so we’ve left them out.

Safety Findings by Study Type

Sorted by study type, BPC-157’s safety record has a broad animal base, a narrow human tip, and a regulatory assessment that points to unknowns. The table lists each finding with its source, species and size, so the weight of each one is easy to see.

What Animal Toxicology Studies Measured

Xu’s 2020 program looked for general toxicity, genetic damage, and harm to pregnancy and offspring across four animal species. Nothing toxic turned up at the levels used. That’s useful screening data, and it has clear limits as a predictor of what would happen in people.

Preclinical safety packages like this follow a familiar pattern. General toxicity studies give animals the compound and then check body weight, blood chemistry, organ weights and tissue under the microscope. Genotoxicity tests check whether a compound damages DNA. Reproductive studies look at pregnancy and the developing young.

“No observed toxicity” in that setting means the researchers didn’t detect harm at the amounts and durations they chose, in those animals. It can’t tell you about reactions specific to humans, about rare events, about interactions with medicines, or about exposure longer than the study ran. Those are the gaps human trials exist to fill, and for BPC-157 those trials haven’t happened.

How Little Human Safety Data Exists

Published human safety data on BPC-157 cover 30 people across three small studies. Only one, a 2-person intravenous pilot, was designed to measure safety. None was randomized or placebo-controlled, and none followed participants long term. A 2025 systematic review found no rigorous assessment of BPC-157 safety in humans.

For perspective, a typical first-in-human phase 1 trial enrolls dozens of healthy volunteers and checks them repeatedly over weeks. Phase 3 trials, where less common side effects start to surface, often enroll thousands. BPC-157’s entire published human record is smaller than a single phase 1 cohort.

Size isn’t the only gap. A phase 1 trial also measures how a compound moves through the body, how long it stays in the blood, and what happens as the amount is increased step by step, with a doctor reviewing every reported symptom against a placebo group. None of that pharmacology has been published for BPC-157 in people. A Boston team of pain specialists made the same point in an August 2026 review of regenerative peptides: for BPC-157 and its peers, the clinical record in people is thin, and FDA approval is absent for most.

Vasireddi’s 2025 orthopedic systematic review got there from another direction: 35 of 36 studies were preclinical, and human safety hadn’t been rigorously studied. A drug company did test BPC-157 under the code PL 14736 for bowel inflammation in the 2000s, but no full results from those trials have been published.

Theoretical Risks Researchers Have Raised

Three theoretical risks come up in the research and regulatory literature: that BPC-157’s promotion of new blood vessels could, in principle, feed tumor growth; that its links to the nitric oxide system raise questions about blood pressure and heart effects; and, per the FDA, that it may trigger immune reactions. None has been tested in people.

Angiogenesis and tumour-growth signalling

🧪 and 🐭 BPC-157’s best-documented mechanism is angiogenesis. Work by Hsieh’s group, published in 2017, traced this to VEGFR2, a receptor central to new vessel growth. Tumors depend on new blood vessels too, and several approved cancer drugs work by blocking VEGF signaling. That’s where the concern comes from. No study has found that BPC-157 starts or speeds tumor growth, and no study has been designed to check.

Nitric oxide, blood pressure and heart questions

🐭 Nitric oxide helps set blood-vessel tone and blood pressure. Rat experiments from Croatia, pulled together in Seiwerth’s 2018 review, report that BPC-157 interacts with this signaling gas. In those rat experiments the effects were generally described as protective. Whether the same interaction could shift blood pressure or heart rhythm in people is unknown.

Immunogenicity and the FDA’s risk assessment

🏛️ Immunogenicity means the immune system recognizing a substance as foreign and reacting to it. In its compounding safety-risk listing, dated April 22, 2026, the FDA wrote that BPC-157 “may pose risk for immunogenicity for certain routes of administration.” The agency added that it “lacks sufficient information to know whether the drug would cause harm when administered to humans.” This is a regulatory assessment of missing data, and it isn’t based on a new study.

Organ Questions: Liver, Heart, Kidneys and Hormones

Research on BPC-157 and specific organs is limited to animal studies and one 2-person human pilot. Rat studies describe liver and heart protection in injury models, the human pilot found no change in liver or kidney blood markers, and no study has measured effects on testosterone.

Read the table with the sample sizes in mind. “No change in 2 people over a few days” is a starting observation. It can’t show an organ is unaffected across a population or over months.

Purity, Contamination and Product Quality Risks

For research-grade BPC-157, product quality is the most concrete risk. No drug-manufacturing inspector checks how research vials are produced, and outside lab testing keeps finding gaps between label and contents. The FDA also flags peptide-related impurities as a concern for BPC-157 specifically.

University of Michigan researchers Christopher Mendias and Tariq Awan pooled independent lab results for consumer-marketed research peptides in a 2026 preprint and reported extensive variability, both in purity and in how much peptide each vial held. It hasn’t been peer-reviewed yet. Live Science reported in July 2026 that many peptides sold in the US are ordered from overseas, with purity and quality control among the main concerns physicians raised.

Endotoxins deserve a sentence of their own. They’re fragments of bacterial cell walls that survive even when the bacteria are dead, and they can provoke fever and inflammation in very small amounts. Testing for them follows a standard method (USP chapter <85>), and many research-peptide certificates of analysis don’t include it.

The risks this creates are practical: a different compound than labeled, less or more peptide than stated, synthesis by-products, or bacterial endotoxins. A batch-specific certificate of analysis that you confirm with the testing lab is the main check available. The step-by-step process is in our COA checking guide.

Why Anecdotal Reports Can’t Show Cause

A symptom reported after using BPC-157 doesn’t show that BPC-157 caused it, any more than a good outcome shows it worked. Coincidence, placebo and nocebo effects, unknown product contents and selective posting can all produce the same stories. Controlled studies exist to sort these apart.

• Coincidence: headaches, nausea and fatigue are common in everyday life, so some people will notice them after trying anything new.
• Nocebo effect: expecting side effects makes people more likely to notice and report them, the mirror image of placebo.
• Unknown contents: if a vial holds impurities or a different compound, the symptom may have nothing to do with BPC-157.
• Self-selection: people with dramatic experiences, good or bad, are the ones most likely to post.
• Other substances: people who try research peptides often try several at once, which makes it impossible to pin a symptom on any single one.

A controlled trial handles all of these by giving a matching placebo to a comparison group and counting symptoms in both. If headaches turn up at the same rate in each group, the compound isn’t the cause. That simple comparison is what BPC-157’s safety literature is still missing.

Regulatory and Sports Status

As of October 12, 2026, BPC-157 has no FDA approval. A withdrawn compounding nomination took it out of Category 2 in April 2026, FDA advisers then favored listing it for compounding by 8 votes to 6 in July, and no rule has followed yet. Anti-doping rules bar it for athletes year-round.

FDA categories. Nominated compounding ingredients wait in interim FDA groups during review, and the second group is the one reserved for safety red flags. BPC-157 stayed in that group until its nominator pulled out in April 2026. The agency’s updated page now shows it in the withdrawn table, and the safety notes quoted above are still printed beside its name.

Compounding vote. Advisers met on July 23, 2026 and voted 8 to 6 in favor of adding BPC-157 to the 503A Bulks List, one member abstaining, AJMC reported. FDA staff reviewers had recommended against it, citing a lack of quality safety and efficacy data. The recommendation isn’t binding.

Sport. BPC-157 appears by name under S0 on the World Anti-Doping Agency’s list, the class for substances with no government approval for human therapy, and it stays there for 2027. USADA has published its own warning about it.

Broader US rules for research compounds are covered in are research peptides legal in the US?

BPC-157 in Blends

BPC-157 appears in combinations such as KLOW and Wolverine, alongside peptides like TB-500. Safety testing of BPC-157 combinations hasn’t been published, so the evidence on combined safety is thinner still than the evidence for BPC-157 alone.

Each added compound brings its own unknowns, and combinations add the question of interactions. A blend also complicates quality control, because a certificate of analysis has to confirm every ingredient and its amount separately, and a single purity figure can hide a missing or underfilled peptide. Two of KLOW’s ingredients, BPC-157 and TB-500, are both studied for blood-vessel growth and cell migration, which puts the angiogenesis question in sharper focus for the blend. Our page on KLOW side effects looks at each ingredient and the blend as a whole.

FAQs

What side effects have been reported in BPC-157 research?

Published studies list none. Xu’s four-species animal program detected no toxicity, and investigators in the three small human studies logged no adverse events. Symptoms described online are anecdotal and haven’t been linked to BPC-157 by any controlled study.

Have studies found effects on the liver?

Nothing harmful to the liver has been reported. Animal toxicology showed no liver damage, Croatian rat experiments describe protection in liver-injury models, and liver enzymes stayed flat in the two volunteers of the 2025 pilot. Larger human data don’t exist.

What does research say about BPC-157 and the heart?

Croatian rat experiments describe protective effects in drug-induced heart rhythm models and interactions with the nitric oxide system. The 2-person human pilot found no change in heart markers. Effects on human blood pressure or heart rhythm haven’t been studied.

Has BPC-157 been studied for effects on testosterone?

No. No animal or human study has measured BPC-157’s effect on testosterone. The 2-person pilot checked thyroid markers, which didn’t change, but sex hormones weren’t part of it.

Is there long-term safety data on BPC-157?

No. The longest animal studies ran for weeks, and the human studies followed participants for days to months with no systematic safety monitoring beyond the 2-person pilot. No study has looked at long-term or repeated exposure in people.

Has the FDA raised safety concerns about BPC-157?

Yes. The FDA’s April 2026 compounding page says BPC-157 may pose a risk of immunogenicity for certain routes, may involve peptide-related impurities, and that the agency lacks enough information to know whether it would cause harm in humans.

Is BPC-157 on the WADA Prohibited List?

Yes. It’s named under S0, WADA’s class for non-approved substances, so athletes can’t use it at any point in the season. The list approved in September 2026 for use from 2027 leaves that entry unchanged.

Conclusion

BPC-157’s safety story is mostly blank pages. The animal toxicology is clean, the human data cover 30 people, and the open questions about blood vessels, immune reactions and product quality haven’t been tested. Read any confident claim, positive or negative, against that backdrop. Our BPC-157 guide covers everything else about the compound.